Graphene Stock Alert: Graphene Experts Dr. Polyakova and Dr. Stolyarov Added to Lomiko Team (TSX-V: LMR) to Create Research and Development Department

VANCOUVER, BRITISH COLUMBIA and NEW YORK, NEW YORK - June 7, 2013 (Investorideas.com mining stocks newswire) LOMIKO METALS INC. (TSX VENTURE:LMR)(LMRMF)(DH8B.F) (Europe: ISIN: CA54163Q1028, WKN: A0Q9W7) (the "Company") reports that Dr. Elena Polyakova and Dr. Daniel Stolyarov have joined Lomiko Metals Inc. to create a Research and Development Department. Primary tasks for the Research and Development Department will be to oversee and coordinate the research activities on conversion of the graphite into graphene, which are currently underway. The department will also oversee end use projects in conjunction with customers of Graphene Laboratories Inc. which include leading universities, Fortune 500 as well as startup companies, world-wide.

"We've been working with Dr. Polyakova and Dr. Stolyarov to develop an action plan for Lomiko Metals. With their help Lomiko is positioned to participate in the graphene revolution.", said Paul Gill, CEO of Lomiko, "Building an R&D capacity means Lomiko will have a head start on the commercial, end use applications which will drive the graphene-graphite business in the future."
Dr. Elena Polyakova founded Graphene Laboratories in 2009 as President and Chief Executive Officer. Since founding Graphene Laboratories, the company has grown to be the leading manufacturer and supplier of graphene materials. Dr. Polyakova is an invited speaker at many international forums and conferences, and her input on the graphene industry is regularly published by journalists covering business and technology.
She received her Masters' degree in Physics and Applied Mathematics with honors from the Moscow Institute of Physics and Technology, and her Ph.D. in Chemistry from the University of Southern California. During Dr. Polyakova's post-doctoral work at Columbia University, her work on graphene was published in many leading peer-reviewed journals, which she co-authored with Nobel and Kalvi prize winners, as well as members of the National Academy of Sciences. It was then that she realized the commercial potential of graphene, which led to the founding of Graphene Laboratories, Inc.
Dr. Daniel Stolyarov co-founded Graphene Laboratories in 2009 and has since served as Chief Technology Officer. At Graphene Laboratories, he leads efforts to introduce new materials to the Graphene Supermarket product line. He also overviews all production efforts and leads all collaborative R&D projects of Graphene Labs. His work continues to play a critical role in securing Graphene Labs place as a leader in the manufacture and sale of 2D materials.
He received his Masters' degree in Physics and Applied Mathematics with honors from the Moscow Institute of Physics and Technology, and his Ph.D. in Physical Chemistry from the University of Southern California. During his academic career, his work on graphene was published in many leading peer-reviewed journals, which he co-authored with Nobel and Kalvi prize winners, as well as members of the National Academy of Sciences.
Dr. Polyakova and Dr. Stolyarov will each receive $ 50,000 per year under a contract of service.
For more information, review the website at www.lomiko.com.
On Behalf of the Board
A. Paul Gill, Chief Executive Officer
We seek safe harbor.
Contact:
Lomiko Metals Inc.
A. Paul Gill
604-729-5312
info@lomiko.com
www.lomiko.com

Disclaimer: The following news is paid for and /or published as information only for our readers.Investorideas.com is a third party publisher of news and research. Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All Investment involves risk and possible loss of all investment. Disclaimer in full, Investorideas.com Disclosure Please read individual disclosures for featured stocks.
Disclaimer: LMR compensates Investorideas for annual news distribution and publication: seven thousand five hundred in equivalent shares for debt
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info